| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 31 | 2021 | 246 | 4.040 |
Why?
|
| Infant, Extremely Premature | 22 | 2025 | 37 | 3.130 |
Why?
|
| Child | 125 | 2025 | 4477 | 2.840 |
Why?
|
| Antipsychotic Agents | 18 | 2022 | 302 | 2.720 |
Why?
|
| Psychotic Disorders | 14 | 2022 | 160 | 2.670 |
Why?
|
| Mental Disorders | 17 | 2025 | 756 | 2.540 |
Why?
|
| Autism Spectrum Disorder | 12 | 2023 | 180 | 2.490 |
Why?
|
| Adolescent | 107 | 2025 | 6195 | 2.190 |
Why?
|
| Schizophrenia, Childhood | 19 | 2018 | 21 | 2.180 |
Why?
|
| Schizophrenia | 19 | 2022 | 267 | 2.010 |
Why?
|
| Magnetic Resonance Imaging | 27 | 2022 | 2147 | 1.740 |
Why?
|
| Intellectual Disability | 4 | 2024 | 167 | 1.660 |
Why?
|
| Autistic Disorder | 8 | 2023 | 149 | 1.660 |
Why?
|
| Child Development Disorders, Pervasive | 8 | 2021 | 45 | 1.560 |
Why?
|
| Brain | 23 | 2022 | 1554 | 1.480 |
Why?
|
| Schizophrenic Psychology | 14 | 2018 | 68 | 1.450 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 14 | 2022 | 158 | 1.320 |
Why?
|
| Humans | 165 | 2025 | 62868 | 1.230 |
Why?
|
| Emotions | 4 | 2023 | 223 | 1.130 |
Why?
|
| Cognition | 12 | 2023 | 481 | 1.130 |
Why?
|
| Infant, Newborn | 25 | 2025 | 1348 | 1.050 |
Why?
|
| Risperidone | 7 | 2012 | 25 | 1.010 |
Why?
|
| Child Psychiatry | 6 | 2020 | 40 | 0.980 |
Why?
|
| Mood Disorders | 6 | 2009 | 72 | 0.950 |
Why?
|
| Mental Health | 7 | 2025 | 364 | 0.950 |
Why?
|
| Anxiety Disorders | 6 | 2023 | 192 | 0.910 |
Why?
|
| Male | 101 | 2025 | 29552 | 0.900 |
Why?
|
| Female | 105 | 2025 | 32566 | 0.890 |
Why?
|
| Neuropsychological Tests | 12 | 2018 | 390 | 0.880 |
Why?
|
| Comorbidity | 13 | 2024 | 1119 | 0.840 |
Why?
|
| Antimanic Agents | 7 | 2017 | 31 | 0.840 |
Why?
|
| Limbic System | 3 | 2009 | 27 | 0.830 |
Why?
|
| Developmental Disabilities | 5 | 2022 | 113 | 0.830 |
Why?
|
| Child Abuse | 3 | 2020 | 90 | 0.830 |
Why?
|
| Child Development | 5 | 2022 | 83 | 0.790 |
Why?
|
| Depressive Disorder, Major | 4 | 2021 | 254 | 0.790 |
Why?
|
| Cognition Disorders | 7 | 2018 | 220 | 0.790 |
Why?
|
| Gyrus Cinguli | 5 | 2015 | 57 | 0.770 |
Why?
|
| Child Behavior Disorders | 3 | 2021 | 37 | 0.770 |
Why?
|
| Self-Injurious Behavior | 1 | 2022 | 47 | 0.760 |
Why?
|
| Psychiatric Status Rating Scales | 28 | 2022 | 393 | 0.750 |
Why?
|
| Mental Health Services | 2 | 2024 | 277 | 0.740 |
Why?
|
| Lithium Carbonate | 7 | 2017 | 12 | 0.740 |
Why?
|
| Editorial Policies | 5 | 2023 | 55 | 0.730 |
Why?
|
| Child, Preschool | 26 | 2022 | 1962 | 0.680 |
Why?
|
| Interpersonal Relations | 2 | 2019 | 151 | 0.660 |
Why?
|
| Age of Onset | 21 | 2014 | 175 | 0.650 |
Why?
|
| Neuroimaging | 4 | 2020 | 154 | 0.650 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 554 | 0.640 |
Why?
|
| Basal Ganglia | 4 | 2013 | 34 | 0.640 |
Why?
|
| Alpha Rhythm | 1 | 2019 | 3 | 0.620 |
Why?
|
| Neurobiology | 2 | 2009 | 5 | 0.620 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2014 | 397 | 0.610 |
Why?
|
| Electroencephalography | 3 | 2021 | 147 | 0.610 |
Why?
|
| Infant, Premature, Diseases | 3 | 2025 | 47 | 0.600 |
Why?
|
| Clozapine | 9 | 2007 | 33 | 0.590 |
Why?
|
| Benzodiazepines | 6 | 2012 | 100 | 0.580 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2021 | 120 | 0.580 |
Why?
|
| Publishing | 4 | 2020 | 92 | 0.580 |
Why?
|
| Siblings | 1 | 2018 | 44 | 0.580 |
Why?
|
| Gestational Age | 9 | 2024 | 189 | 0.570 |
Why?
|
| Molindone | 4 | 2012 | 7 | 0.570 |
Why?
|
| Psychotropic Drugs | 5 | 2022 | 81 | 0.560 |
Why?
|
| gamma-Aminobutyric Acid | 3 | 2015 | 75 | 0.550 |
Why?
|
| Biomedical Research | 5 | 2022 | 264 | 0.550 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 221 | 0.540 |
Why?
|
| Pediatrics | 3 | 2018 | 250 | 0.540 |
Why?
|
| Glutamine | 2 | 2015 | 46 | 0.530 |
Why?
|
| Epilepsy | 5 | 2021 | 110 | 0.510 |
Why?
|
| Neurodevelopmental Disorders | 5 | 2021 | 40 | 0.490 |
Why?
|
| Cerebral Palsy | 3 | 2021 | 19 | 0.490 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2014 | 17 | 0.480 |
Why?
|
| Biofeedback, Psychology | 2 | 2005 | 6 | 0.470 |
Why?
|
| Adolescent Psychiatry | 3 | 2020 | 18 | 0.470 |
Why?
|
| Adult | 34 | 2024 | 16672 | 0.470 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 74 | 0.470 |
Why?
|
| Vagus Nerve | 2 | 2005 | 21 | 0.470 |
Why?
|
| Information Dissemination | 2 | 2015 | 115 | 0.470 |
Why?
|
| Electric Stimulation Therapy | 2 | 2005 | 27 | 0.460 |
Why?
|
| Anxiety | 7 | 2024 | 423 | 0.460 |
Why?
|
| Cognitive Dysfunction | 5 | 2020 | 331 | 0.460 |
Why?
|
| Magnetics | 2 | 2005 | 53 | 0.460 |
Why?
|
| Brain Mapping | 8 | 2012 | 232 | 0.450 |
Why?
|
| Irritable Mood | 1 | 2014 | 16 | 0.450 |
Why?
|
| Cohort Studies | 16 | 2024 | 2549 | 0.450 |
Why?
|
| Quinolones | 1 | 2014 | 29 | 0.440 |
Why?
|
| White Matter | 1 | 2015 | 123 | 0.440 |
Why?
|
| Pregnancy | 13 | 2023 | 2326 | 0.430 |
Why?
|
| Piperazines | 1 | 2014 | 78 | 0.430 |
Why?
|
| Pandemics | 4 | 2024 | 664 | 0.430 |
Why?
|
| Emotional Intelligence | 1 | 2013 | 4 | 0.430 |
Why?
|
| United States | 21 | 2024 | 7744 | 0.430 |
Why?
|
| Weight Gain | 4 | 2011 | 170 | 0.430 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2013 | 13 | 0.420 |
Why?
|
| Achievement | 4 | 2021 | 27 | 0.410 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2021 | 157 | 0.410 |
Why?
|
| Oxytocin | 1 | 2013 | 45 | 0.410 |
Why?
|
| Prospective Studies | 15 | 2025 | 3263 | 0.410 |
Why?
|
| Life Change Events | 1 | 2013 | 66 | 0.410 |
Why?
|
| Infant | 9 | 2022 | 1623 | 0.410 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 1640 | 0.400 |
Why?
|
| Young Adult | 17 | 2022 | 4655 | 0.400 |
Why?
|
| Child Health | 4 | 2022 | 31 | 0.390 |
Why?
|
| Fragile X Syndrome | 2 | 2022 | 27 | 0.390 |
Why?
|
| Tryptamines | 3 | 2016 | 13 | 0.380 |
Why?
|
| Severity of Illness Index | 16 | 2020 | 1541 | 0.360 |
Why?
|
| Corpus Callosum | 1 | 2010 | 42 | 0.350 |
Why?
|
| Aging | 6 | 2019 | 743 | 0.340 |
Why?
|
| Follow-Up Studies | 12 | 2025 | 2444 | 0.340 |
Why?
|
| Cerebral Cortex | 6 | 2015 | 258 | 0.330 |
Why?
|
| Risk | 3 | 2018 | 377 | 0.330 |
Why?
|
| Intelligence | 3 | 2022 | 55 | 0.330 |
Why?
|
| Sex Factors | 10 | 2018 | 975 | 0.320 |
Why?
|
| Age Factors | 12 | 2021 | 1556 | 0.290 |
Why?
|
| Social Environment | 2 | 2025 | 93 | 0.290 |
Why?
|
| Metformin | 1 | 2009 | 73 | 0.290 |
Why?
|
| Neuroglia | 2 | 2007 | 79 | 0.290 |
Why?
|
| Thalamus | 3 | 2010 | 66 | 0.280 |
Why?
|
| Lithium Compounds | 2 | 2018 | 8 | 0.280 |
Why?
|
| Migraine Disorders | 3 | 2016 | 41 | 0.280 |
Why?
|
| Health Services Needs and Demand | 2 | 2024 | 207 | 0.270 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 214 | 0.270 |
Why?
|
| Biomarkers | 6 | 2021 | 1388 | 0.270 |
Why?
|
| Empirical Research | 1 | 2006 | 15 | 0.270 |
Why?
|
| Periodicals as Topic | 2 | 2020 | 174 | 0.260 |
Why?
|
| Enterocolitis, Necrotizing | 2 | 2025 | 18 | 0.260 |
Why?
|
| Quality of Life | 3 | 2025 | 1221 | 0.260 |
Why?
|
| Drug Therapy | 1 | 2006 | 55 | 0.260 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2015 | 294 | 0.250 |
Why?
|
| Health Status | 2 | 2019 | 433 | 0.250 |
Why?
|
| Anticonvulsants | 1 | 2006 | 108 | 0.250 |
Why?
|
| Homeless Youth | 1 | 2005 | 8 | 0.240 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2005 | 5 | 0.240 |
Why?
|
| Mitochondrial Diseases | 1 | 2005 | 22 | 0.240 |
Why?
|
| Double-Blind Method | 10 | 2018 | 739 | 0.240 |
Why?
|
| Health Education | 1 | 2006 | 188 | 0.230 |
Why?
|
| Child Behavior | 3 | 2016 | 64 | 0.230 |
Why?
|
| Research Design | 2 | 2018 | 573 | 0.230 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 1252 | 0.230 |
Why?
|
| Prevalence | 2 | 2024 | 1366 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2015 | 667 | 0.220 |
Why?
|
| Pirenzepine | 2 | 2001 | 5 | 0.220 |
Why?
|
| Prefrontal Cortex | 3 | 2015 | 121 | 0.200 |
Why?
|
| Social Adjustment | 3 | 2002 | 35 | 0.200 |
Why?
|
| Parents | 5 | 2022 | 381 | 0.200 |
Why?
|
| Intestinal Perforation | 1 | 2022 | 16 | 0.200 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 31 | 0.200 |
Why?
|
| Depressive Disorder | 1 | 2005 | 285 | 0.200 |
Why?
|
| Puberty | 2 | 2005 | 59 | 0.190 |
Why?
|
| Asperger Syndrome | 1 | 2002 | 2 | 0.190 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 163 | 0.190 |
Why?
|
| Nerve Growth Factors | 2 | 2019 | 27 | 0.190 |
Why?
|
| Growth and Development | 1 | 2021 | 9 | 0.190 |
Why?
|
| Child Nutrition Disorders | 1 | 2021 | 19 | 0.180 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6548 | 0.180 |
Why?
|
| Cerebral Intraventricular Hemorrhage | 1 | 2021 | 9 | 0.180 |
Why?
|
| Social Skills | 1 | 2021 | 10 | 0.180 |
Why?
|
| Malnutrition | 1 | 2021 | 41 | 0.180 |
Why?
|
| Leukoencephalopathies | 1 | 2021 | 25 | 0.180 |
Why?
|
| Premature Birth | 1 | 2022 | 113 | 0.180 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2021 | 57 | 0.170 |
Why?
|
| Inflammation | 3 | 2023 | 1142 | 0.170 |
Why?
|
| Functional Laterality | 4 | 2010 | 138 | 0.170 |
Why?
|
| Risk Factors | 6 | 2020 | 5309 | 0.170 |
Why?
|
| Psychomotor Performance | 3 | 2019 | 137 | 0.170 |
Why?
|
| Chorioamnionitis | 1 | 2020 | 14 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2015 | 853 | 0.170 |
Why?
|
| Communication Disorders | 2 | 2013 | 17 | 0.170 |
Why?
|
| Depression | 3 | 2024 | 884 | 0.170 |
Why?
|
| Treatment Outcome | 10 | 2018 | 5596 | 0.170 |
Why?
|
| Logistic Models | 4 | 2021 | 1275 | 0.160 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2020 | 40 | 0.160 |
Why?
|
| Academic Performance | 1 | 2019 | 7 | 0.160 |
Why?
|
| Education, Special | 1 | 2019 | 11 | 0.160 |
Why?
|
| Organ Size | 5 | 2019 | 171 | 0.160 |
Why?
|
| Social Behavior | 2 | 2013 | 91 | 0.160 |
Why?
|
| Temperament | 2 | 2014 | 20 | 0.160 |
Why?
|
| Peer Review, Research | 1 | 2020 | 47 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 364 | 0.160 |
Why?
|
| Psychiatry | 1 | 2021 | 118 | 0.160 |
Why?
|
| Language Disorders | 4 | 2010 | 25 | 0.160 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 94 | 0.150 |
Why?
|
| Placenta | 1 | 2019 | 59 | 0.150 |
Why?
|
| Patient Dropouts | 1 | 2018 | 49 | 0.150 |
Why?
|
| Racism | 1 | 2020 | 88 | 0.150 |
Why?
|
| Statistics as Topic | 2 | 2011 | 148 | 0.150 |
Why?
|
| Remedial Teaching | 1 | 1998 | 2 | 0.150 |
Why?
|
| Infant Mortality | 1 | 2018 | 20 | 0.150 |
Why?
|
| Hippocampus | 4 | 2015 | 267 | 0.150 |
Why?
|
| Checklist | 2 | 2016 | 73 | 0.150 |
Why?
|
| Linear Models | 4 | 2019 | 409 | 0.140 |
Why?
|
| Disclosure | 1 | 2018 | 54 | 0.140 |
Why?
|
| Conflict of Interest | 1 | 2018 | 37 | 0.140 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2017 | 39 | 0.140 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 60 | 0.140 |
Why?
|
| Epigenomics | 2 | 2019 | 62 | 0.140 |
Why?
|
| Specialization | 1 | 2018 | 81 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2024 | 934 | 0.140 |
Why?
|
| Bias | 1 | 2018 | 112 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2019 | 292 | 0.130 |
Why?
|
| Software | 1 | 2020 | 383 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 204 | 0.130 |
Why?
|
| Caudate Nucleus | 3 | 2007 | 25 | 0.130 |
Why?
|
| Putamen | 3 | 2007 | 21 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 218 | 0.130 |
Why?
|
| Physicians | 1 | 2022 | 464 | 0.130 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 54 | 0.130 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 28 | 0.130 |
Why?
|
| Cytoskeleton | 1 | 1997 | 138 | 0.130 |
Why?
|
| Erythropoietin | 1 | 2016 | 39 | 0.130 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2016 | 37 | 0.130 |
Why?
|
| Interleukin-8 | 1 | 2016 | 88 | 0.130 |
Why?
|
| Phenotype | 4 | 2023 | 1197 | 0.130 |
Why?
|
| Gray Matter | 1 | 2016 | 35 | 0.130 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 46 | 0.130 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 1 | 2015 | 5 | 0.120 |
Why?
|
| Students | 1 | 1998 | 218 | 0.120 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 2652 | 0.120 |
Why?
|
| Internal-External Control | 1 | 2015 | 33 | 0.120 |
Why?
|
| Actins | 1 | 1997 | 259 | 0.120 |
Why?
|
| Behavior Rating Scale | 1 | 2015 | 2 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 166 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 1194 | 0.120 |
Why?
|
| Psychology, Child | 1 | 2015 | 7 | 0.120 |
Why?
|
| Genetics | 1 | 2015 | 13 | 0.120 |
Why?
|
| Psychology, Adolescent | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2015 | 28 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 205 | 0.120 |
Why?
|
| Pregnancy Complications | 3 | 2015 | 378 | 0.120 |
Why?
|
| Creatinine | 1 | 2015 | 135 | 0.120 |
Why?
|
| Psychometrics | 4 | 2023 | 377 | 0.120 |
Why?
|
| Valproic Acid | 2 | 2006 | 26 | 0.110 |
Why?
|
| Brief Psychiatric Rating Scale | 2 | 2007 | 13 | 0.110 |
Why?
|
| Aripiprazole | 1 | 2014 | 5 | 0.110 |
Why?
|
| Prodromal Symptoms | 1 | 2014 | 17 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2015 | 152 | 0.110 |
Why?
|
| Temporal Lobe | 2 | 2009 | 46 | 0.110 |
Why?
|
| Income | 1 | 2015 | 169 | 0.110 |
Why?
|
| Anger | 1 | 2014 | 23 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 458 | 0.110 |
Why?
|
| Educational Status | 1 | 2015 | 273 | 0.110 |
Why?
|
| Psychopathology | 1 | 2013 | 21 | 0.110 |
Why?
|
| Parental Death | 1 | 2013 | 3 | 0.110 |
Why?
|
| Haloperidol | 5 | 1997 | 16 | 0.110 |
Why?
|
| Hallucinations | 1 | 2013 | 16 | 0.110 |
Why?
|
| Oxytocics | 1 | 2013 | 14 | 0.100 |
Why?
|
| Psychotherapy | 2 | 2021 | 96 | 0.100 |
Why?
|
| Ambulatory Care | 2 | 2006 | 311 | 0.100 |
Why?
|
| Bullying | 1 | 2013 | 16 | 0.100 |
Why?
|
| Functional Neuroimaging | 1 | 2013 | 14 | 0.100 |
Why?
|
| Methylphenidate | 1 | 2013 | 19 | 0.100 |
Why?
|
| Cerebellum | 2 | 2013 | 94 | 0.100 |
Why?
|
| Disorders of Excessive Somnolence | 3 | 2002 | 16 | 0.100 |
Why?
|
| Comprehension | 3 | 2024 | 134 | 0.100 |
Why?
|
| Globus Pallidus | 2 | 2007 | 25 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2015 | 233 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 65 | 0.100 |
Why?
|
| Database Management Systems | 1 | 2012 | 19 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 730 | 0.100 |
Why?
|
| Motion Perception | 1 | 2012 | 5 | 0.100 |
Why?
|
| Information Systems | 1 | 2012 | 29 | 0.100 |
Why?
|
| Norway | 3 | 2016 | 23 | 0.100 |
Why?
|
| Mothers | 1 | 2015 | 275 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 964 | 0.090 |
Why?
|
| Glutamic Acid | 2 | 2015 | 98 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 775 | 0.090 |
Why?
|
| Health Resources | 1 | 2012 | 93 | 0.090 |
Why?
|
| Proteins | 1 | 1997 | 751 | 0.090 |
Why?
|
| Analysis of Variance | 6 | 2012 | 608 | 0.090 |
Why?
|
| Social Class | 2 | 2024 | 133 | 0.090 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2010 | 8 | 0.090 |
Why?
|
| Dominance, Cerebral | 1 | 2010 | 33 | 0.090 |
Why?
|
| Myelin Sheath | 1 | 2010 | 37 | 0.090 |
Why?
|
| Mass Screening | 1 | 2016 | 689 | 0.090 |
Why?
|
| Aggression | 2 | 2014 | 64 | 0.090 |
Why?
|
| Vitamins | 1 | 2011 | 81 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 864 | 0.080 |
Why?
|
| Time Factors | 5 | 2013 | 3749 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2015 | 497 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2015 | 749 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2013 | 378 | 0.080 |
Why?
|
| Frontal Lobe | 2 | 2013 | 65 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 192 | 0.080 |
Why?
|
| Models, Biological | 2 | 2017 | 1181 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2022 | 78 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 139 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 453 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2009 | 45 | 0.080 |
Why?
|
| Facial Expression | 1 | 2009 | 16 | 0.080 |
Why?
|
| Infant, Premature | 2 | 2022 | 183 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2010 | 131 | 0.080 |
Why?
|
| Obesity | 2 | 2022 | 1230 | 0.080 |
Why?
|
| Amygdala | 2 | 2007 | 83 | 0.080 |
Why?
|
| Genotype | 3 | 2016 | 666 | 0.080 |
Why?
|
| Language | 1 | 2010 | 143 | 0.080 |
Why?
|
| Internet | 1 | 2012 | 464 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2558 | 0.070 |
Why?
|
| Cerebral Ventricles | 3 | 1996 | 29 | 0.070 |
Why?
|
| Antidepressive Agents | 2 | 2006 | 225 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2010 | 287 | 0.070 |
Why?
|
| Triglycerides | 1 | 2009 | 244 | 0.070 |
Why?
|
| Occipital Lobe | 1 | 2007 | 17 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 863 | 0.070 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2006 | 9 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2006 | 11 | 0.070 |
Why?
|
| Integration Host Factors | 1 | 2006 | 2 | 0.070 |
Why?
|
| Nucleus Accumbens | 1 | 2007 | 43 | 0.070 |
Why?
|
| Triazines | 1 | 2006 | 16 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 231 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2017 | 562 | 0.070 |
Why?
|
| Weight Loss | 1 | 2009 | 272 | 0.070 |
Why?
|
| Amines | 1 | 2006 | 30 | 0.070 |
Why?
|
| Psychology | 1 | 2006 | 44 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2009 | 485 | 0.060 |
Why?
|
| Child Reactive Disorders | 1 | 2006 | 1 | 0.060 |
Why?
|
| Protons | 2 | 2022 | 62 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 55 | 0.060 |
Why?
|
| Fructose | 1 | 2006 | 38 | 0.060 |
Why?
|
| Body Weight | 3 | 2017 | 377 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2022 | 989 | 0.060 |
Why?
|
| Hospitalization | 2 | 2021 | 1346 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 369 | 0.060 |
Why?
|
| Telencephalon | 1 | 2005 | 10 | 0.060 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2005 | 8 | 0.060 |
Why?
|
| Retinopathy of Prematurity | 1 | 2025 | 13 | 0.060 |
Why?
|
| Adolescent Health | 1 | 2025 | 14 | 0.060 |
Why?
|
| Hospitals, Psychiatric | 1 | 2005 | 54 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2009 | 864 | 0.060 |
Why?
|
| Insulin | 1 | 2009 | 687 | 0.060 |
Why?
|
| Sexuality | 2 | 2002 | 25 | 0.060 |
Why?
|
| Reaction Time | 4 | 1999 | 124 | 0.060 |
Why?
|
| Atrophy | 1 | 2005 | 83 | 0.060 |
Why?
|
| Hospitals, Pediatric | 1 | 2005 | 52 | 0.060 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2025 | 31 | 0.060 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2002 | 36 | 0.060 |
Why?
|
| Peer Group | 1 | 2025 | 104 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2005 | 1115 | 0.060 |
Why?
|
| Maternal Age | 1 | 2024 | 34 | 0.060 |
Why?
|
| Maternal Health | 1 | 2024 | 15 | 0.060 |
Why?
|
| Sex Ratio | 1 | 2004 | 8 | 0.060 |
Why?
|
| Health Literacy | 1 | 2024 | 81 | 0.050 |
Why?
|
| Biotransformation | 1 | 2003 | 23 | 0.050 |
Why?
|
| Character | 1 | 2003 | 2 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2003 | 47 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2003 | 146 | 0.050 |
Why?
|
| Hair Follicle | 1 | 2022 | 35 | 0.050 |
Why?
|
| Pursuit, Smooth | 3 | 1996 | 3 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 231 | 0.050 |
Why?
|
| Self Report | 2 | 2015 | 371 | 0.050 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2022 | 38 | 0.050 |
Why?
|
| Task Performance and Analysis | 1 | 2023 | 126 | 0.050 |
Why?
|
| Biological Phenomena | 1 | 2002 | 4 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 729 | 0.050 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2012 | 30 | 0.050 |
Why?
|
| Echoencephalography | 1 | 2021 | 13 | 0.050 |
Why?
|
| Interdisciplinary Research | 1 | 2021 | 3 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 170 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2003 | 203 | 0.050 |
Why?
|
| India | 1 | 2021 | 157 | 0.040 |
Why?
|
| Appetite | 1 | 2001 | 16 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2020 | 22 | 0.040 |
Why?
|
| Neural Pathways | 2 | 2012 | 98 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 462 | 0.040 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2020 | 9 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 463 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 727 | 0.040 |
Why?
|
| Tics | 1 | 2000 | 7 | 0.040 |
Why?
|
| Psychosocial Support Systems | 1 | 2020 | 12 | 0.040 |
Why?
|
| Tourette Syndrome | 1 | 2000 | 15 | 0.040 |
Why?
|
| Organophosphorus Compounds | 1 | 2020 | 31 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2001 | 101 | 0.040 |
Why?
|
| Social Isolation | 1 | 2020 | 34 | 0.040 |
Why?
|
| Middle Aged | 5 | 2022 | 17394 | 0.040 |
Why?
|
| Domestic Violence | 1 | 2020 | 39 | 0.040 |
Why?
|
| Research | 1 | 2021 | 192 | 0.040 |
Why?
|
| Reference Values | 2 | 2015 | 335 | 0.040 |
Why?
|
| Caregivers | 1 | 2022 | 268 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2001 | 106 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 55 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2019 | 76 | 0.040 |
Why?
|
| Angiopoietin-1 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Family | 1 | 2020 | 240 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2018 | 33 | 0.040 |
Why?
|
| Hearing Disorders | 1 | 2018 | 10 | 0.040 |
Why?
|
| Prognosis | 2 | 2018 | 1727 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 35 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2001 | 358 | 0.040 |
Why?
|
| Seizures | 2 | 2016 | 144 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2020 | 219 | 0.040 |
Why?
|
| Mathematics | 1 | 1998 | 34 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 217 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 179 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 5411 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2018 | 64 | 0.040 |
Why?
|
| Executive Function | 1 | 2018 | 64 | 0.040 |
Why?
|
| Galvanic Skin Response | 1 | 1997 | 24 | 0.040 |
Why?
|
| Language Tests | 2 | 2010 | 39 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 392 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1078 | 0.030 |
Why?
|
| Office Visits | 1 | 2017 | 47 | 0.030 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 1997 | 6 | 0.030 |
Why?
|
| Homovanillic Acid | 1 | 1997 | 6 | 0.030 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1997 | 9 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1997 | 11 | 0.030 |
Why?
|
| Blinking | 1 | 1996 | 4 | 0.030 |
Why?
|
| Menarche | 1 | 1997 | 37 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2017 | 49 | 0.030 |
Why?
|
| Survivors | 1 | 2018 | 170 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1997 | 174 | 0.030 |
Why?
|
| Reading | 1 | 1998 | 92 | 0.030 |
Why?
|
| Half-Life | 1 | 2017 | 77 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1998 | 140 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 90 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1534 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 60 | 0.030 |
Why?
|
| Attention | 1 | 1998 | 148 | 0.030 |
Why?
|
| Self-Help Devices | 1 | 2016 | 5 | 0.030 |
Why?
|
| Microcephaly | 1 | 2016 | 14 | 0.030 |
Why?
|
| Communication | 1 | 2021 | 569 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 319 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 49 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 384 | 0.030 |
Why?
|
| Program Evaluation | 1 | 1998 | 486 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 317 | 0.030 |
Why?
|
| Prolactin | 2 | 2010 | 40 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2015 | 45 | 0.030 |
Why?
|
| Anthropometry | 1 | 2015 | 86 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 154 | 0.030 |
Why?
|
| Binding Sites | 1 | 1997 | 902 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1079 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 66 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2015 | 80 | 0.030 |
Why?
|
| Glucose | 1 | 1997 | 470 | 0.030 |
Why?
|
| Affect | 1 | 2015 | 125 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2014 | 7 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 74 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 18 | 0.030 |
Why?
|
| Hostility | 1 | 2014 | 18 | 0.030 |
Why?
|
| Curriculum | 1 | 1998 | 586 | 0.030 |
Why?
|
| Asthma | 1 | 2018 | 433 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 1595 | 0.030 |
Why?
|
| Mental Recall | 1 | 2014 | 91 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 1997 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1005 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1140 | 0.030 |
Why?
|
| Phosphocreatine | 1 | 2013 | 25 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 147 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 295 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 482 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 113 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2014 | 158 | 0.020 |
Why?
|
| Phosphates | 1 | 2013 | 92 | 0.020 |
Why?
|
| Software Design | 1 | 2012 | 28 | 0.020 |
Why?
|
| Aged | 2 | 2022 | 14271 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2012 | 25 | 0.020 |
Why?
|
| Speech Disorders | 2 | 2006 | 17 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 78 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2012 | 90 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2012 | 124 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 336 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 455 | 0.020 |
Why?
|
| Homeostasis | 1 | 2014 | 368 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2051 | 0.020 |
Why?
|
| Observer Variation | 2 | 2005 | 211 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 25 | 0.020 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2010 | 5 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2010 | 22 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 111 | 0.020 |
Why?
|
| Karyotyping | 1 | 2010 | 47 | 0.020 |
Why?
|
| Cerebellar Cortex | 1 | 2010 | 10 | 0.020 |
Why?
|
| Rest | 1 | 2010 | 44 | 0.020 |
Why?
|
| Consciousness | 1 | 2010 | 12 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 840 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2010 | 63 | 0.020 |
Why?
|
| Wakefulness | 1 | 2010 | 42 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2010 | 293 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2010 | 120 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2010 | 97 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 367 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2010 | 177 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 178 | 0.020 |
Why?
|
| Oxygen | 1 | 2010 | 316 | 0.020 |
Why?
|
| Rats | 1 | 2010 | 1980 | 0.020 |
Why?
|
| Sertraline | 1 | 2006 | 58 | 0.020 |
Why?
|
| Body Height | 1 | 2006 | 68 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2007 | 152 | 0.020 |
Why?
|
| Faculty | 1 | 2006 | 53 | 0.020 |
Why?
|
| Animals | 2 | 2010 | 20617 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 2006 | 79 | 0.020 |
Why?
|
| Missouri | 1 | 2005 | 10 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 1996 | 299 | 0.010 |
Why?
|
| Physicians, Family | 1 | 2005 | 75 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 3027 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 469 | 0.010 |
Why?
|
| Boston | 1 | 2002 | 251 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2001 | 52 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 786 | 0.010 |
Why?
|
| Patient Admission | 1 | 2000 | 190 | 0.010 |
Why?
|
| Habituation, Psychophysiologic | 1 | 1997 | 4 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1997 | 41 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1997 | 36 | 0.010 |
Why?
|
| Orientation | 1 | 1997 | 27 | 0.010 |
Why?
|
| Syndrome | 1 | 1998 | 179 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1998 | 416 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 42 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1997 | 186 | 0.010 |
Why?
|
| Neutropenia | 1 | 1996 | 67 | 0.010 |
Why?
|
| Eye Movements | 1 | 1996 | 83 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 1996 | 194 | 0.010 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 1994 | 3 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1994 | 262 | 0.010 |
Why?
|